140P Tislelizumab combined with lenvatinib and transarterial chemoembolization(TACE) neoadjuvant treatment in resectable CNLC IIa-IIb hepatocellular carcinoma: A prospective, single-arm, phase II study
Background: Until recently, neoadjuvant therapy for HCC has been limited by a lack of effective approaches.Prior studies have shown that patients (pts) achieving major pathological response (MPR) with neoadjuvant therapy have improved recurrencefree survival (RFS) in early-stage hepatocellular carcinoma (HCC).This prospective study aimed to explore the efficacy and safety of TACE combined with lenvatinib and tislelizumab in high-risk resectable HCC pts.
Authors
- Z. Zhang
- Gang Huang (ORCID: https://orcid.org/0000-0001-8697-2238)
- Jie Chen (ORCID: https://orcid.org/0000-0002-2658-9525)
- Lifeng Wang (ORCID: https://orcid.org/0000-0001-5095-6842)
- Qi Liu (ORCID: https://orcid.org/0000-0001-5378-6404)
- Yidan Chen (ORCID: https://orcid.org/0000-0003-3232-6403)
- Hao Lü (ORCID: https://orcid.org/0000-0002-2241-6598)
- Lingpeng Yang (ORCID: https://orcid.org/0000-0002-4229-9464)
- Xiaohua Wu (ORCID: https://orcid.org/0000-0002-2271-2514)
Institutions
- Fujian Medical University (CN)
- Zhangzhou Municipal Hospital of Fujian Province (CN)
- First Affiliated Hospital of Fujian Medical University (CN)
- Putian University (CN)
Publication Details
- Journal
- Immuno-Oncology Technology
- Published
- 2024-12-01
- DOI
- https://doi.org/10.1016/j.iotech.2024.100769
- Primary Topic
- Hepatocellular Carcinoma Treatment and Prognosis
- Type
- article
- Field-Weighted Citation Impact
- 0.00